CDT Equity Inc. Receives Nasdaq Delisting Notice for Untimely 10-Q Filing
CDT sits 20% above its 52-week low of $0.793.
Summary
CDT Equity Inc. received a Nasdaq deficiency letter due to its failure to timely file its Q1 2026 Form 10-Q, putting its stock listing at risk.
Key Events · Corporate Governance and Compliance · CDT
-
Nasdaq Delisting Notice Received
On May 21, 2026, CDT Equity Inc. received a deficiency letter from Nasdaq for non-compliance with Listing Rule 5250(c)(1) due to the untimely filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026.
-
Risk to Nasdaq Listing
The notice has no immediate effect on the company's listing or trading, but it signals a potential delisting if the issue is not resolved. This follows a previous 'going concern' warning in the company's 10-K filed on April 15, 2026.
-
Compliance Deadline
The company must submit a plan to regain compliance with the Periodic Filing Requirement by July 20, 2026.
-
Company's Response
CDT Equity Inc. anticipates filing its Form 10-Q as soon as the review process is complete, aiming to regain compliance.
Analysis · CDT · Life Sciences
CDT Equity Inc. received a deficiency letter from Nasdaq for failing to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. This is a critical compliance issue that directly threatens the company's Nasdaq listing, adding significant risk to a company already facing a 'going concern' warning from its recent 10-K. While there is no immediate delisting, the company must submit a plan to regain compliance by July 20, 2026, or face further action. Failure to meet reporting obligations often indicates underlying operational or financial control weaknesses.
At the time of this filing, CDT was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $0.79 to $848.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.